BRD4 and neoplasm: By concurrently degrading BRD4 and mitigating immunosuppressive pathways, SPP-ARV-825 outperformed both free ARV-825 and non-targeted micelles, demonstrating the promise of brain-targeted polymeric micelle drugs in surmounting BBB constraints and effectively modulating the tumor microenvironment.